Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 5 (May)

1. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
   Cancer Res, 65(9): 3707-15. [Abstract] [Full-text]
2. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
   Clin Cancer Res, 11(9): 3425-32. [Abstract] [Full-text]
3. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma.
   Blood, 105(10): 4051-9. [Abstract] [Full-text]
4. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
   Blood, 105(10): 4021-7. [Abstract] [Full-text]
5. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
   Blood, 105(10): 3995-4003. [Abstract] [Full-text]
6. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis.
   Acta Haematol, 113(3): 181-9. [Abstract] [Full-text]
7. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
   Acta Haematol, 113(3): 155-62. [Abstract] [Full-text]
8. Anti-IL-5 and hypereosinophilic syndromes.
   Clin Immunol, 115(1): 51-60. [Abstract] [Full-text]
9. KIT-positive gastrointestinal stromal tumor in a 22-year-old male chimpanzee (Pan troglodites).
   Vet Pathol, 42(3): 362-5. [Abstract] [Full-text]
10. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
    Cancer, 103(10): 2099-108. [Abstract] [Full-text]
11. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Cancer, 103(10): 2128-31. [Abstract] [Full-text]
12. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
    Oncogene, 24(20): 3257-67. [Abstract] [Full-text]
13. Molecular dynamics and protein function.
    Proc Natl Acad Sci U S A, 102(19): 6679-85. [Abstract] [Full-text]
14. Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics.
    World J Surg, 29(3): 357-61; discussion 362. [Abstract] [Full-text]
15. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
    Clin Cancer Res, 11(10): 3668-77. [Abstract] [Full-text]
16. Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
    Biochem Pharmacol, 69(11): 1585-94. [Abstract] [Full-text]
17. Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells.
    Int J Biochem Cell Biol, 37(8): 1709-26. [Abstract] [Full-text]
18. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Cancer Genet Cytogenet, 159(2): 164-7. [Abstract] [Full-text]
19. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
    Br J Cancer, 92(10): 1881-91. [Abstract] [Full-text]
20. Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death.
    Cell Death Differ, 12(6): 627-36. [Abstract] [Full-text]
21. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
    J Surg Oncol, 90(3): 195-207; discussion 207. [Abstract] [Full-text]
22. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
    Exp Hematol, 33(6): 682-8. [Abstract] [Full-text]
23. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
    Leukemia, 19(6): 1034-41. [Abstract] [Full-text]
24. Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations.
    Int J Hematol, 81(4): 310-4. [Abstract] [Full-text]
25. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Int J Hematol, 81(4): 307-9. [Abstract] [Full-text]
26. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
    Radiology, 235(3): 892-8. [Abstract] [Full-text]
27. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
    Am J Respir Crit Care Med, 171(11): 1279-85. [Abstract] [Full-text]
28. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
    Cancer Lett, 225(1): 1-26. [Abstract] [Full-text]
29. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
    FASEB J, 19(8): 960-2. [Abstract] [Full-text]
30. Imatinib blocks spontaneous mechanical activities in the adult mouse small intestine: possible inhibition of c-Kit signaling.
    Pharmacology, 74(2): 95-9. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.